Novo Nordisk's (NVO) weight loss drug Wegovy (semaglutide), which can be prescribed to Medicare beneficiaries who are both obese and have cardiovascular disease, could cost the system up to $145B ...

How the change could impact Novo Nordisk. The amount Medicare spent on Ozempic, Wegovy, and Rybelsus between November 2023 and October 2024 represents roughly 36% of Wall Street's consensus ...

Novo Nordisk has hired three new lobbying firms over the past three months, all of which disclosed being solely focused on issues related to obesity and Medicare coverage of anti-obesity drugs.

Novo Nordisk is trying to reverse a 20-year-old ban on coverage of drugs used for weight loss under Medicare, the federal health insurance program primarily for people 65 and older.

Novo Nordisk anticipates that the next round of medications targeted ... the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D for the first ...

Novo Nordisk's weight loss drug, Wegovy, receives FDA approval for reducing cardiovascular risk, ... This would make the total addressable Medicare market worth $28 billion for Novo Nordisk.

Novo Nordisk is trying to reverse a 20-year-old ban on coverage of drugs used for weight loss under Medicare, the federal health insurance program primarily for people 65 and older.

Medicare. Novo Nordisk. Obesity. STAT+. To submit a correction request, please visit our Contact Us page. Trending. Proposed cuts could have ‘catastrophic effect,’ 110 biomedical, health… ...